Entera Bio (ENTX.Q) has announced the final 6-month bone mineral density (BMD) results from its Phase 2 clinical trial of EB613 for the treatment of osteoporosis. “We are very…
Latest News
Are stock markets about to crash hard?
Revive Therapeutics (RVV.CN) announces FDA acceptance of meeting request
Top 5 Gainers and Losers: LAC.TO, WEED.TO, OML.V
BC Bud Corp (BCBC.C) breathes new life into the cannabis space, up 3x in two months
Top 5 Gainers and Losers: TMQ.TO, GLM.CN, AGMR.V
Standard Uranium (STND.V) reports on exploration at Sun Dog Project